Spark Therapeutics, Inc. (ONCE)
(Delayed Data from NSDQ)
$108.03 USD
+1.03 (0.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $108.08 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$108.03 USD
+1.03 (0.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $108.08 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Week Begins with Biotech Mergers
by Zacks Equity Research
Week Begins with Biotech Mergers
Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More
by Mark Vickery
Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).
BioMarin Files MAA to EMA for Gene Therapy of Hemophilia A
by Zacks Equity Research
BioMarin (BMRN) submits an MAA in Europe for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
Biogen Ends Enrollment in Eye Disorder Study on Gene Therapy
by Zacks Equity Research
Biogen (BIIB) completes enrollment in the global phase III STAR clinical study evaluating the gene therapy timrepigene emparvovec for the treatment of a rare, inherited retinal disorder.
Will Spark Therapeutics (ONCE) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche Posts Solid Sales for First 9 Months of '19, Ups View
by Zacks Equity Research
Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.
Roche's (RHHBY) Rituxan Receives FDA Nod for Label Expansion
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for Rituxan to treat children with two rare blood vessel disorders. The company also extends the offer period to acquire Spark Therapeutics.
ETFs Poised to Benefit from Gene Editing Revolution
by Sweta Jaiswal, FRM
Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.
Analysts Estimate Spark Therapeutics (ONCE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised
by Zacks Equity Research
Roche's (RHHBY) performance in the first half of 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.
Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)
by Zacks Equity Research
Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.
Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline
by Zacks Equity Research
Roche (RHHBY) presents new positive data on Hemlibra, reinforcing its efficacy and safety. Moreover, the deadline of the impending merger with Spark has been extended.
Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study
by Zacks Equity Research
Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.
BioMarin (BMRN) to File for Hemophilia A Candidate in Q4
by Zacks Equity Research
BioMarin (BMRN) plans to file regulatory applications for gene therapy candidate for severe hemophilia A in the fourth quarter of 2019.
Roche Receives FTC Request for Further Data on Spark Buyout
by Zacks Equity Research
Roche (RHHBY) gets additional information request from FTC for the pending Spark acquisition.
Options Traders Expect Huge Moves in Spark Therapeutics (ONCE) Stock
by Zacks Equity Research
Investors need to pay close attention to Spark Therapeutics (ONCE) stock based on the movements in the options market lately.
Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems
by Zacks Equity Research
Roche (RHHBY) gets FDA clearance for the expansion of its leading testing menu.
Will Spark Therapeutics (ONCE) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs
by Zacks Equity Research
Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.
Ophthotech Gets Rights to Gene Therapy for BEST Disease
by Zacks Equity Research
Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.
Biotechnology Market on a Tear: 5 ETFs in Spotlight
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
by Indrajit Bandyopadhyay
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
Health Day Checkup of Medical ETFs: 5 Top Picks
by Sanghamitra Saha
M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.
Sangamo Rises on Positive Phase I/II Hemophilia Study Data
by Zacks Equity Research
Sangamo (SGMO) and partner Pfizer announce encouraging data from a phase I/II study evaluating their gene therapy candidate for treating hemophilia A.
Roche Extends Offer Period for Spark Therapeutics Acquisition
by Zacks Equity Research
Roche (RHHBY) withdraws its Premerger Notification and Report Form in connection with the pending acquisition of Spark Therapeutics.